share_log

SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-The Carlyle Group Inc.(4.1%),Carlyle Holdings I GP Inc.(4.1%), etc.

SEC announcement ·  May 13 16:11
Summary by Moomoo AI
On May 9, 2024, eFFECTOR Therapeutics, Inc., a biopharmaceutical company, was the subject of a Schedule 13D/A filing with the U.S. Securities and Exchange Commission (SEC) by The Carlyle Group and associated entities. The filing, which is an amendment to a previous Schedule 13D, reports that The Carlyle Group and several related entities collectively own 193,195 shares of eFFECTOR Therapeutics' common stock, representing 4.1% of the company. This ownership stake is a result of a 1-for-25 reverse stock split effected by eFFECTOR Therapeutics on January 9, 2024. The Carlyle Group Inc. is the ultimate parent entity in a chain of ownership that includes Carlyle Holdings I GP Inc., Carlyle Holdings I GP Sub L.L.C., Carlyle Holdings I L.P., CG Subsidiary Holdings L.L...Show More
On May 9, 2024, eFFECTOR Therapeutics, Inc., a biopharmaceutical company, was the subject of a Schedule 13D/A filing with the U.S. Securities and Exchange Commission (SEC) by The Carlyle Group and associated entities. The filing, which is an amendment to a previous Schedule 13D, reports that The Carlyle Group and several related entities collectively own 193,195 shares of eFFECTOR Therapeutics' common stock, representing 4.1% of the company. This ownership stake is a result of a 1-for-25 reverse stock split effected by eFFECTOR Therapeutics on January 9, 2024. The Carlyle Group Inc. is the ultimate parent entity in a chain of ownership that includes Carlyle Holdings I GP Inc., Carlyle Holdings I GP Sub L.L.C., Carlyle Holdings I L.P., CG Subsidiary Holdings L.L.C., TC Group, L.L.C., Carlyle Investment Management L.L.C., Carlyle Genesis UK LLC, Abingworth LLP, and Abingworth Bioventures VI LP. The filing also indicates that as of May 9, 2024, the reporting entities ceased to be beneficial owners of more than five percent of the outstanding shares of eFFECTOR Therapeutics' common stock. No transactions in the common stock were reported by the entities in the 60 days prior to the filing.

This announcement is a separate document:

Doc 1

Doc 2

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more